Itron heads into its April 30 Q1 earnings release with the stock under real pressure and short sellers holding a meaningful position.
Short interest is the dominant setup signal here. At 11.5% of the free float — up 8% over the past month — bears have been building steadily into the print. The ORTEX short score of 57 reflects that accumulated pressure. Days to cover runs nearly nine sessions based on official FINRA data, meaning any reversal would take time to unwind. The lending market, however, offers little additional squeeze fuel: borrow costs are modest at 0.45% and availability remains loose, suggesting the short position is well-established rather than stressed.
Options positioning reinforces the cautious tone. The put/call ratio has run above its 20-day average for the better part of the past two weeks, reaching 1.01 most recently — about 1.1 standard deviations above the mean of 0.86. That's not an extreme reading, but the sustained tilt toward puts is consistent with hedging ahead of the number. The stock itself has lost nearly 8% over the past week and 5% in the most recent session alone, closing at $82.69. The February print produced a 1-day decline of 3.3% and a 5-day drop of 6.1%, adding context for how this name has behaved around prior releases.
The analyst community is broadly constructive but visibly less confident. TD Cowen cut its target to $130 from $145 this morning — maintaining a Buy — while JPMorgan trimmed to $113 from $133 earlier this month, keeping its Overweight. Oppenheimer went the other way, nudging its target up to $135 from $133, also on April 16. The consensus mean target of $127.50 implies roughly 54% upside from current levels, a gap that reflects how far the stock has fallen from where the Street was pricing it just months ago. The bull case centres on Itron's ARR run-rate approaching $368 million, 24% growth, a strengthening software mix, and FCF conversion targets hit two years early. Bears point to a 2024-2027 revenue CAGR revised to -0.3%, flat 2026 revenue guidance, and a projected 7% EBITDA decline — a deterioration in the fundamental growth story that peers have not matched. EV/EBITDA has compressed to 10x, down about 3% over the past month, suggesting valuation is already adjusting, but forward EPS momentum ranks in the bottom quartile of the universe.
The print is therefore a test of whether Itron's software and services pivot can generate enough margin and backlog momentum to counter the revenue stagnation narrative — and whether management's tone on supply chain and macro uncertainty gives the Street any reason to close that widening gap between targets and price.
See the live data behind this article on ORTEX.
Open ITRI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
